BVNKF: AI 评分 52/100 — AI 分析 (4月 2026)

Bavarian Nordic A/S is a biotechnology company specializing in the development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio includes vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Bavarian Nordic A/S is a vaccine developer focused on infectious diseases, with a portfolio including approved vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola. The company leverages its MVA-BN technology platform to develop and commercialize vaccines, positioning it as a key player in the global vaccine market.

BVNKF是做什么的？

Bavarian Nordic A/S, founded in 1992 and headquartered in Hellerup, Denmark, is a biotechnology company dedicated to developing, manufacturing, and commercializing life-saving vaccines. The company's core business revolves around its portfolio of vaccines targeting infectious diseases. Bavarian Nordic's flagship products include the non-replicating smallpox and monkeypox vaccines, marketed under the names IMVAMUNE, IMVANEX, and JYNNEOS. These vaccines have gained prominence due to their role in global health security. In addition to its smallpox and monkeypox vaccines, Bavarian Nordic offers a rabies vaccine for human use under the Rabipur/RabAvert brand and a tick-borne encephalitis vaccine under the Encepur brand. The company also provides an Ebola vaccine under the MVABEA name. Bavarian Nordic is actively engaged in research and development, with several vaccine candidates in various stages of clinical trials. These include MVA-BN (freeze-dried) for smallpox, MVA-BN RSV for respiratory syncytial virus, ABNCoV2 for SARS-CoV-2, and TAEK-VAC for advanced HER2 and brachyury-expressing cancers. Bavarian Nordic operates globally, with a presence in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan.

BVNKF的投资论点是什么？

Bavarian Nordic presents a compelling investment case driven by its established portfolio of approved vaccines and promising pipeline of vaccine candidates. The company's revenue is supported by ongoing demand for its smallpox and monkeypox vaccines, particularly in response to global health concerns. The Phase III clinical trials for MVA-BN RSV represent a significant growth catalyst, targeting a large market with substantial unmet needs. With a P/E ratio of 10.33 and a profit margin of 22.2%, Bavarian Nordic demonstrates financial stability and profitability. However, potential risks include clinical trial failures, competition from other vaccine manufacturers, and reliance on government contracts.

BVNKF在哪个行业运营？

The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant growth potential. The global vaccine market is driven by increasing awareness of infectious diseases and government initiatives to promote vaccination. Bavarian Nordic competes with other vaccine manufacturers, including BRCTF (BriaCell Therapeutics Corp), GLPGF (Galapagos NV), HAWPY (Haw Par Corp Ltd), HBMHF (HBM Healthcare Investments AG), and HYPMY (Hypera S.A.). Bavarian Nordic's focus on specialized vaccines and its established manufacturing capabilities provide a competitive edge in this dynamic market.

Biotechnology

Healthcare

BVNKF有哪些增长机遇？

MVA-BN RSV Vaccine: Bavarian Nordic's MVA-BN RSV vaccine, currently in Phase III clinical trials, targets the respiratory syncytial virus, a significant cause of respiratory illness in infants and older adults. The RSV vaccine market is projected to reach billions of dollars in the coming years, presenting a substantial growth opportunity for Bavarian Nordic. Successful completion of clinical trials and regulatory approval could drive significant revenue growth.
ABNCoV2 Vaccine: The ABNCoV2 vaccine candidate, which has completed Phase II clinical trials for the treatment of SARS-CoV-2, represents another growth opportunity for Bavarian Nordic. While the initial surge in demand for COVID-19 vaccines has subsided, there remains a need for booster shots and variant-specific vaccines. Bavarian Nordic's ABNCoV2 vaccine could capture a share of this market.
TAEK-VAC Cancer Vaccine: Bavarian Nordic is developing TAEK-VAC, a cancer vaccine targeting advanced HER2 and brachyury-expressing cancers. This vaccine is currently in Phase I/II clinical trials. The cancer vaccine market is a rapidly growing area, driven by advances in immunotherapy and personalized medicine. Successful development and commercialization of TAEK-VAC could provide a significant long-term growth driver for Bavarian Nordic.
Geographic Expansion: Bavarian Nordic has the opportunity to expand its geographic presence and increase sales in emerging markets. Many developing countries have a high burden of infectious diseases and a need for affordable vaccines. By partnering with local distributors and participating in global health initiatives, Bavarian Nordic can tap into these markets and drive revenue growth.
Strategic Partnerships: Bavarian Nordic can pursue strategic partnerships and collaborations to expand its product portfolio and accelerate its research and development efforts. The company already has license and collaboration agreements with AdaptVac, National Cancer Institute, and Public Health Service. Additional partnerships with other biotechnology companies, research institutions, and government agencies could provide access to new technologies, funding, and expertise.

Market capitalization of $2.20 billion reflects investor confidence in Bavarian Nordic's vaccine portfolio and growth prospects.
P/E ratio of 10.33 indicates a potentially undervalued stock compared to its peers in the biotechnology industry.
Profit margin of 22.2% demonstrates efficient operations and strong profitability.
Gross margin of 48.5% highlights the company's ability to generate substantial revenue from its vaccine sales.
Beta of 1.09 suggests that the stock's volatility is similar to the overall market.

BVNKF提供哪些产品和服务？

Develops non-replicating smallpox and monkeypox vaccines.
Manufactures and commercializes rabies vaccines for human use.
Offers tick-borne encephalitis vaccines.
Provides Ebola vaccines.
Develops vaccines for respiratory syncytial virus (RSV).
Develops vaccines for SARS-CoV-2.
Develops cancer vaccines targeting HER2 and brachyury-expressing cancers.

BVNKF如何赚钱？

Develops and manufactures vaccines for infectious diseases.
Commercializes vaccines through direct sales and distribution agreements.
Partners with governments and international organizations to supply vaccines.
Generates revenue from vaccine sales, licensing agreements, and research grants.

Governments and public health agencies.
Hospitals and clinics.
Travelers and individuals seeking protection against infectious diseases.
Military and defense organizations.

Proprietary MVA-BN technology platform for vaccine development.
Established manufacturing capabilities for vaccine production.
Regulatory approvals and market access for key vaccines.
Strong relationships with governments and international organizations.

什么因素可能推动BVNKF股价上涨？

Upcoming: Phase III clinical trial results for MVA-BN RSV vaccine.
Upcoming: Regulatory approval decisions for vaccine candidates.
Ongoing: Government contracts and procurement agreements for existing vaccines.
Ongoing: Expansion into new geographic markets.
Ongoing: Strategic partnerships and collaborations.

BVNKF的主要风险是什么？

Potential: Clinical trial failures and regulatory setbacks.
Potential: Competition from larger pharmaceutical companies.
Potential: Patent expirations and generic competition.
Ongoing: Reliance on government contracts and funding.
Ongoing: Public skepticism towards vaccines.

BVNKF的核心优势是什么？

Established portfolio of approved vaccines.
Proprietary MVA-BN technology platform.
Strong relationships with governments and international organizations.
Experienced management team.

BVNKF的劣势是什么？

Reliance on government contracts.
Competition from larger pharmaceutical companies.
Potential for clinical trial failures.
Limited product diversification.

BVNKF有哪些机遇？

Expansion into emerging markets.
Development of new vaccines for unmet medical needs.
Strategic partnerships and collaborations.
Increased demand for vaccines due to global health threats.

BVNKF面临哪些威胁？

Regulatory changes and challenges.
Patent expirations and generic competition.
Economic downturns and reduced government spending.
Public skepticism towards vaccines.

BVNKF的竞争对手是谁？

BriaCell Therapeutics Corp — Focuses on cancer immunotherapy. — (BRCTF)
Galapagos NV — Develops medicines for inflammatory diseases. — (GLPGF)
Haw Par Corp Ltd — Diversified company with healthcare interests. — (HAWPY)
HBM Healthcare Investments AG — Invests in healthcare companies. — (HBMHF)
Hypera S.A. — Brazilian pharmaceutical company. — (HYPMY)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Paul John Chaplin
Headquarters: Hellerup, DK
Employees: 1,645
Founded: 2010

AI Insight

AI analysis pending for BVNKF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S is a biotechnology company focused on developing, manufacturing, and commercializing life-saving vaccines. The company's core business revolves around its portfolio of vaccines targeting infectious diseases, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola. Bavarian Nordic leverages its proprietary MVA-BN technology platform to develop innovative vaccine candidates and collaborates with governments, international organizations, and other biotechnology companies to expand its reach and impact on global health.

What do analysts say about BVNKF stock?

Analyst coverage of BVNKF stock is limited due to its OTC listing. However, the company's financial performance, vaccine pipeline, and market position are key factors considered in valuation assessments. The potential for revenue growth from existing vaccines and new product launches is a positive factor. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. Analyst consensus is Unknown.

What are the main risks for BVNKF?

The main risks for BVNKF include clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, reliance on government contracts, and public skepticism towards vaccines. Clinical trial failures can significantly impact the company's pipeline and future revenue potential. Regulatory setbacks can delay or prevent the approval of new vaccines. Competition from larger pharmaceutical companies with greater resources and market access can erode market share. Reliance on government contracts makes the company vulnerable to changes in government spending and priorities. Public skepticism towards vaccines can reduce demand and impact sales.